Trials
6 active
17 in total · 7 in the EU
What this is
- How it works
- A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
- How it’s given
- “A single intravenous (i.v.) infusion of CAR-positive viable T cells.”In the company’s words, NCT04094311 on ClinicalTrials.gov
- Tested for
- B-cell Acute Lymphoblastic Leukemia (2 trials), Diffuse Large B-cell Lymphoma, Follicular Lymphoma (FL)
- Main trialPhase 3
- “This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only for Part 1, in addition to safety, key efficacy of CTL019 will also be evaluated.”In the company’s words, NCT04094311 on ClinicalTrials.gov
- Other names
- CTL019
Other drugs for B-cell Acute Lymphoblastic Leukemia
- Human immunoglobulin GCSL Behring · Phase 3
- MK-1045Merck & Co. · Phase 2/3
- YK012Excyte Biopharma Ltd · Phase 1/2
- Autologous BCMA/CD19 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous BCMA/CD38 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous BCMA/GPRC5D dual-target CAR-TBeijing Biotech · Phase 1/2
Coming up3
- 31 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- 19 Oct 2027Phase 2 trial completes · ClinicalTrials.gov
- 25 Jul 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Mar 2027 | Study of Out of Specification for Tisagenlecleucel | |
| Phase 3Active, not recruiting | 25 Jul 2028 | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma | |
| Phase 2Active, not recruiting | 19 Oct 2027 | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients | |
| Phase 3Completed | 13 Oct 2020 | Phase III B in Acute Lymphoblastic Leukemia | |
| Phase 2Completed | 21 Jan 2020 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients | |
| Phase 2Completed | 24 Nov 2020 | Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma | |
| Phase 2Completed | 27 Jul 2021 | Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients | |
| Phase 2Terminated | 19 Oct 2021 | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) | |
| Phase 2Withdrawn | 31 Oct 2022 | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) | |
| Phase 2Withdrawn | 30 Nov 2022 | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL | |
| Phase 2Completed | 22 Dec 2022 | Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients | |
| Phase 1Completed | 20 Jul 2021 | Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients | |
| Phase 1Terminated | 1 Nov 2021 | Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients | |
| Phase 3Authorised | not given | Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-CellTherapy | |
| Phase 1/2Authorised | not given | CAPTIRALL _ Combination of an Anti-PD1 antibody with Tisagenlecleucel Reinfusion in children, adolescents and young adults with Acute Lymphoblastic Leukemia after loss of persistence | |
| Phase 4Authorised | not given | Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector Cell-Associated Neurotoxicity Syndrome : the VESICANS study | |
| Phase 1/2Halted | not given | Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, relapse or detectable measurable residual disease. Phase I/II clinical trial (MERMAID1) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026